Malignant melanoma is an unpredictable disease, known to metastasize early even in thin melanomas.
Historically the presence of intraabdominal metastasis meant poor prognosis with a 5-year survival of less
than 20%. That has significantly changed with effective systemic therapy (EST), with most recent studies
reporting 5-year survival of up to 50%. Metastasecectomy for resistant disease has been considered in Stage
IV disease, however there is very little literature on the combination of EST and metastasectomy. This report
describes a case of Stage IV malignant melanoma patient who developed resistant disease within her
gallbladder fundic wall. She underwent open cholecystectomy, with complete metabolic response at 1-year
follow up PET.
Relaxation medical treatment - Malignant melanoma. A case of malignant melanoma patient who died 27 days after operation.
